These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
43. Impact of novel agents followed by autologous hematopoietic stem cell transplantation for multiple myeloma patients aged 65 years or older: a retrospective single Institutional analysis. Minoia C; Pisapia G; Palazzo G; Ingrosso C; Buonanno M; Spinosa C; Prudenzano A; Pricolo G; Mazza P Bone Marrow Transplant; 2015 Nov; 50(11):1486. PubMed ID: 26281030 [No Abstract] [Full Text] [Related]
44. Early relapsed disease of multiple myeloma following up-front HDM-ASCT: a study based on the Danish Multiple Myeloma Registry in the period 2005 to 2014. Helm-Petersen S; Sørrig R; Klausen TW; Preiss B; Frølund UC; Helleberg C; Breinholt M; Andersen MK; Abildgaard N; Gimsing P; Vangsted AJ Leukemia; 2018 Sep; 32(9):2054-2057. PubMed ID: 29500392 [No Abstract] [Full Text] [Related]
45. [Management of bone disease in myeloma patients: zoledronic acid or denosumab?]. Abe M; Miki H; Nakamura S Rinsho Ketsueki; 2015 Aug; 56(8):997-1004. PubMed ID: 26345558 [TBL] [Abstract][Full Text] [Related]
46. Bone Disease in Myeloma: The Claws of CRAB. Fonseca R; Jain T Clin Cancer Res; 2016 Mar; 22(6):1301-3. PubMed ID: 26792259 [TBL] [Abstract][Full Text] [Related]
48. [Treatment of myeloma in the elderly]. Garderet L; Isnard F; Gorin NC Bull Cancer; 2008 May; 95 FMC Onco():F84-8. PubMed ID: 18511373 [TBL] [Abstract][Full Text] [Related]
49. [Management of bone lesions in multiple myeloma]. Hata H; Mitsuya H Gan To Kagaku Ryoho; 2006 Aug; 33(8):1072-6. PubMed ID: 16912524 [TBL] [Abstract][Full Text] [Related]
50. Combination regimens using doxorubicin and pegylated liposomal doxorubicin prior to autologous transplantation in multiple myeloma. Moreau P Expert Rev Anticancer Ther; 2009 Jul; 9(7):885-90. PubMed ID: 19589027 [TBL] [Abstract][Full Text] [Related]
51. [Current therapy concepts in patients with multiple myeloma]. Heyll A; Schneider P; Bauser U; Kobbe G; Hünerlitürkoglu A; Aul C; Haas R Dtsch Med Wochenschr; 2000 Oct; 125(40):1201-9. PubMed ID: 11075253 [No Abstract] [Full Text] [Related]
52. Multiple myeloma : recent progress in diagnosis and treatment. Chou T J Clin Exp Hematop; 2012; 52(3):149-59. PubMed ID: 23269074 [TBL] [Abstract][Full Text] [Related]
53. Root resorption caused by jaw infiltration of multiple myeloma: report of a case and literature review. Troeltzsch M; Oduncu F; Mayr D; Ehrenfeld M; Pautke C; Otto S J Endod; 2014 Aug; 40(8):1260-4. PubMed ID: 25069945 [TBL] [Abstract][Full Text] [Related]
54. Myeloma and the newly diagnosed patient: a focus on treatment and management. Rajkumar SV; Kyle RA; Gertz MA Semin Oncol; 2002 Dec; 29(6 Suppl 17):5-10. PubMed ID: 12520478 [TBL] [Abstract][Full Text] [Related]
56. Evaluation of Frequency of Administration of Intravenous Bisphosphonate and Recurrent Skeletal-Related Events in Patients With Multiple Myeloma. Zhou J; Sweiss K; Han J; Ko NY; Patel PR; Chiu BC; Calip GS JAMA Netw Open; 2021 Jul; 4(7):e2118410. PubMed ID: 34313746 [TBL] [Abstract][Full Text] [Related]
57. Maintenance therapy for multiple myeloma. McCarthy PL; Palumbo A Hematol Oncol Clin North Am; 2014 Oct; 28(5):839-59. PubMed ID: 25212886 [TBL] [Abstract][Full Text] [Related]
58. The role of pre-transplant induction regimens and autologous stem cell transplantation in the era of novel targeted agents. Gay F; Cavallo F; Palumbo A Drugs; 2015 Mar; 75(4):367-75. PubMed ID: 25764394 [TBL] [Abstract][Full Text] [Related]
59. Serum C terminal telopeptide maintains its correlation with bone disease in patients with myeloma even under treatment with bisphosphonates. Pochintesta L; Mangiacavalli S; Cocito F; Pompa A; Albertini R; Pascutto C; Ferretti VV; Cazzola M; Corso A Leuk Lymphoma; 2014 Jun; 55(6):1397-8. PubMed ID: 23931337 [No Abstract] [Full Text] [Related]